Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
29 August 2016 |
Main ID: |
NCT02535130 |
Date of registration:
|
24/08/2015 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Evaluation of Nebulization and Positive Expiratory Pressure Combination
|
Scientific title:
|
|
Date of first enrolment:
|
August 2015 |
Target sample size:
|
15 |
Recruitment status: |
Recruiting |
URL:
|
https://clinicaltrials.gov/show/NCT02535130 |
Study type:
|
Interventional |
Study design:
|
Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
|
Phase:
|
N/A
|
|
Countries of recruitment
|
Belgium
| | | | | | | |
Contacts
|
Name:
|
Anne-Sophie Aubriot, PT |
Address:
|
|
Telephone:
|
+3227647020 |
Email:
|
as.aubriot@gmail.com |
Affiliation:
|
|
| | |
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Stable cystic fibrosis patients older than 16 y.o.
- Healthy subjects
Exclusion Criteria:
- Kidney failure
- No pregnancy
Age minimum:
16 Years
Age maximum:
55 Years
Gender:
Both
|
Health Condition(s) or Problem(s) studied
|
Cystic Fibrosis
|
Healthy Subjects
|
Intervention(s)
|
Drug: amikacine nebulization
|
Device: Positive expiratory pressure
|
Primary Outcome(s)
|
Urinary excretion of amikacin
[Time Frame: 24 hours after the nebulization]
|
Secondary Outcome(s)
|
breathing pattern
[Time Frame: participants will be recorded for the duration of the nebulization, an expected average of 15 minutes]
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|